CONNECT WITH US:
May 07, 2021 01:00 JST
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand
ADELAIDE, AUS, May 07, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).
This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).
In Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology Act 2000. The OGTR administers the Gene Technology Act 2000, and has specific responsibility to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating dealings with GMOs.
The global market for genetic modification therapies is expected to grow from $2.3 billion in 2018 to reach $17.4 billion by 2023, growing at a compound annual growth rate of 49.9% (BCC Research, 2018). The utilization of gene modification technologies used in COVID-19 vaccine products is likely to translate in further growth in this field of therapeutics.
Avance Clinical CEO Yvonne Lungershausen said OGTR accreditation is important for our international clients. "Our clients need to know that their CRO has all the necessary credentials and is capable of delivering the highest of clinical research standards in this exciting and rapidly evolving sector," she said.
Avance Clinical currently has a number of GMO studies underway and is expanding its services further to accommodate increasing global demand.
Take the Quiz: Test your Knowledge about Australian Clinical Trials here.
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit
for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
TANAKA to Provide Pure Gold, Pure Silver, and Pure Bronze Medals for the Tokyo Marathon 2024
Feb 21, 2024 04:00 JST
Fujitsu collaborates with QuTech in development of new technology for freezing electronics to control diamond spin qubits
Feb 20, 2024 21:28 JST
NTT DOCOMO and SK Telecom Release White Paper on Base Station Equipment Utilizing Virtualization Technology
Feb 20, 2024 15:32 JST
NEC Develops AI Technology for Robotics Capable of Autonomous and Advanced Handling of Disorderly Placed Items
Feb 20, 2024 12:03 JST
JCB and The Bicester Collection expand their partnership to offer more luxury shopping opportunities for Asian travellers
Feb 20, 2024 12:00 JST
National High School in the Philippines Built with the Support of Mitsubishi Motors Holds Opening Ceremony
Feb 20, 2024 11:15 JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2024 09:35 JST
TOYOTA GAZOO Racing Finishes Strongly on Swedish Snow
Feb 19, 2024 19:26 JST
MC to Subscribe Shares in TVS Vehicle Mobility Solution in India
Feb 19, 2024 17:42 JST
NEC Enhances Value Added Network Solution Suite to Boost Enterprise Digital Innovation
Feb 19, 2024 16:05 JST
Fujitsu develops technology to speed up quantum circuit computation in quantum simulator by 200 times
Feb 19, 2024 10:26 JST
MHI Recognized by CDP as Being at the Leadership Level for Climate Change Earning A- score
Feb 19, 2024 10:08 JST
MAZDA INNOVATION SPACE TOKYO Opens
Feb 16, 2024 17:29 JST
NEC develops RAN autonomous optimization technology that dynamically controls 5G networks based on user terminal status
Feb 16, 2024 11:42 JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 16, 2024 09:31 JST
PoC Launched to Test Smart-charging Service Using EV Connected Technologies
Feb 15, 2024 16:50 JST
Hitachi Energy and TransnetBW make German grid fit for future
Feb 15, 2024 11:22 JST
JCB Cards are now accepted at Maybank merchant terminals in Singapore
Feb 15, 2024 11:00 JST
Arsaga Partners, Tokyu Land, NTT and DOCOMO to Explore Collaboration for R&D to Create Services with IOWN
Feb 14, 2024 15:40 JST
TMC Announces Personnel Changes in Senior Management
Feb 14, 2024 13:11 JST
More Latest Release >>
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
April 18 2023 11:00 JST
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
January 11 2023 15:00 JST
Avance Clinical Wins International Health Award for Biotech CRO Services
September 28 2022 16:00 JST
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs
September 06 2022 13:00 JST
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022
August 29 2022 18:00 JST
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
April 19 2022 10:00 JST
More Press release >>